STOCK TITAN

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announces the release of its financial results for the twelve months ending December 31, 2023. The company will host a conference call on February 29, 2024, at 4:30 p.m. Eastern time. Participants can register via a provided link and access dial-in options. A live webcast will be available on Lisata's website for replay for 12 months post-call.
Positive
  • None.
Negative
  • None.

BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for twelve months ended December 31, 2023, on Thursday, February 29, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.

Contact:

Investors and Media:

Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com


Lisata Therapeutics, Inc. will report its financial results for the twelve months ended December 31, 2023, on Thursday, February 29, 2024.

The conference call hosted by Lisata Therapeutics, Inc. will take place at 4:30 p.m. Eastern time on February 29, 2024.

Participants can register for the conference call hosted by Lisata Therapeutics, Inc. by using the provided link in the press release.

Participants can access the live webcast of the conference call hosted by Lisata Therapeutics, Inc. under the Investors & News section of Lisata's website.

The replay of the conference call hosted by Lisata Therapeutics, Inc. will be available for 12 months post-call.
Lisata Therapeutics Inc

NASDAQ:LSTA

LSTA Rankings

LSTA Latest News

LSTA Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Basking Ridge

About LSTA

caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.